Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma
Conditions
Brief summary
The purpose of this study is to plan for future clinical trials in patients with metastatic urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT fluoroscopy guidance into bone, lymph node, soft tissue and liver metastases in subjects with metastatic prostate cancer, urothelial carcinoma, or renal cell carcinoma. Pre- and post-injection CT images will be obtained to determine the injection parameters needed for optimal distribution throughout metastases of a given size. A biopsy of the metastatic site will also be obtained to validate expression of the receptor CD155.
Interventions
DRUGIsovue-M 200
Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
Sponsors
Duke University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed diagnosis of adenocarcinoma of the prostate, renal cell carcinoma or urothelial carcinoma. Small cell or neuroendocrine tumors of the prostate are also permitted. 2. Radiographic evidence of at least one bone, lymph node, soft tissue, or liver metastasis, that is amenable to iodinated contrast injection, as judged by the study radiologist 3. Adequate laboratory values: 1. Platelets ≥ 100,000 2. INR ≤ 1.3 4. Age \> 18 years. 5. Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
1. History of intercurrent or past medical or psychiatric illness that would make participation in a research biopsy protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s). 2. Cr \>2.0 3. History of iodinated contrast allergy 4. For patients undergoing research only biopsy: Requirement for anticoagulation with heparin, low molecular weight heparin, clopidogrel, rivaroxaban, dabigatran, apixaban, warfarin, Aggrenox, fondaparux, ticagrelor, etc (aspirin and other NSAIDs are ok but should be held prior to biopsy in accordance with institutional standard of care) 5. Any other contraindication to CT with iodinated contrast, as CT with contrast will be used in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence of iodinated contrast enhancement within the metastasis on post-injection CT | Day 1 |
| Percentage of iodinated contrast enhancement within the metastasis on post-injection CT | Day 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence of tumor CD155 membrane expression in metastatic bone, liver, soft tissue or lymph node specimens. | Day 1 | IHC will be used to assess tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens. |
| Estimated percentage of tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens. | Day 1 | IHC will be used to assess tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens. |
Countries
United States
Outcome results
None listed